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Abstract
Complement activation correlates to rheumatoid arthritis disease activity, and increased
amounts of the complement split product C5a is observed in synovial fluids from rheumatoid
arthritis patients. Blockade of C5a or its receptor (C5aR) is efficacious in several arthritis
models. The aim of this study was to investigate the role of C5a and C5aR in human rheu-
matoid arthritis and psoriatic arthritis–both with respect to expression and function. Synovial
fluid, blood and synovial samples were obtained from rheumatoid arthritis, psoriatic arthritis
and osteoarthritis patients as a less inflammatory arthritis type, and blood from healthy sub-
jects. Cells infiltrating synovial tissue were analysed by immunohistochemistry and flow
cytometry. SF and blood were analysed for biomarkers by flow cytometry or ELISA. The
effect of a blocking anti-human C5aR mAb on leukocyte migration was determined using a
Boyden chamber. Appropriate statistical tests were applied for comparisons. C5aR+ cells
were detected in most rheumatoid arthritis, in all psoriatic arthritis, but not in non-inflamma-
tory control synovia. C5aR+ cells were primarily neutrophils and macrophages. C5aR+ mac-
rophages were mainly found in lymphoid aggregates in close contact with T cells. C5a levels
were increased in both rheumatoid arthritis and psoriatic arthritis synovial fluid compared to
osteoarthritis, and in blood from rheumatoid arthritis compared to healthy subjects. Neutro-
phil and monocyte migration to rheumatoid arthritis synovial fluid was significantly inhibited
by anti-C5aR. The data support that the C5a-C5aR axis may be driving the infiltration of
inflammatory cells into the synovial fluid and synovium in both rheumatoid and psoriatic
arthritis, and suggest that C5a or C5aR may be a promising treatment target in both
diseases.
PLOS ONE | https://doi.org/10.1371/journal.pone.0189017 December 8, 2017 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Hornum L, Hansen AJ, Tornehave D,
Fjording MS, Colmenero P, Wa¨tjen IF, et al. (2017)
C5a and C5aR are elevated in joints of rheumatoid
and psoriatic arthritis patients, and C5aR blockade
attenuates leukocyte migration to synovial fluid.
PLoS ONE 12(12): e0189017. https://doi.org/
10.1371/journal.pone.0189017
Editor: Cordula M. Stover, University of Leicester,
UNITED KINGDOM
Received: September 15, 2017
Accepted: November 18, 2017
Published: December 8, 2017
Copyright: © 2017 Hornum et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files (specifically, files S5-S7).
Funding: The Parker Institute is supported by an
unspecified grant from the OAK Foundation (OCAY-
13-309). Novo Nordisk A/S supported acquisition
of antibodies and some technical assistance, and
the funder provided support in the form of salaries
for authors [LH, AJH, DT, MSF], but did not have
any additional role in the study design, data
Introduction
The complement system plays a central role in the immune system by constituting a non-cellu-
lar system for protection against pathogens via a protease cascade leading to the activation of
several effector molecules downstream of three activation pathways (classical, lectin and alter-
native). Effector molecules include C3b leading to opzonization, the membrane attack com-
plex directly leading to cell lysis, and the formation of anaphylatoxins (C3a and C5a) with
chemotactic and other pro-inflammatory properties [1]. C5a exerts its function on cells
expressing the C5aR receptor. An alternative non-signalling receptor is identified, but the
function of this receptor is disputed, but data indicates that C5L2 functions as a intracellular
inhibitor of C5a-induced C5aR signalling [2, 3].
The complement system is suggested to play a major role in rheumatoid arthritis (RA) path-
ogenesis, where complement activation products are found to be increased in synovial fluid
(SF) to higher levels than in the matching plasma [4]. Moreover, the level of complement acti-
vation correlates with disease activity [5–7]. Complement polymorphism is shown as a likely
player when increasing the concentration of active C5a in RA joints [8].
One of the major effector molecules in the complement system is the split product C5a of
complement C5. This highly proinflammatory molecule acts on C5a-receptor (C5aR) positive
cells, which include granulocytes, monocytes, subsets of macrophages, dendritic cells and mast
cells, while expression on T cells is debated [9, 10]. C5a is a potent chemoattractant, but is also
activating C5aR-positive cells: It induces oxidative bursts and release of effector molecules
from neutrophils, and cytokines from monocytes and macrophages. A number of studies dem-
onstrate, furthermore, that C5a enhances T-cell activation, most likely via action on C5aR-pos-
itive cells [11], and C5a is shown to be upregulated in RA SF [12, 13]. In contrast to RA, no
data exist on the role of complement in the pathogenesis of psoriatic arthritis (PsA) [14].
Complement is necessary in arthritis development in the collagen-induced arthritis (CIA)
model [15], and an active role of C5a has also been implicated in other arthritis models: C5aR
deficiency protects against arthritis in collagen antibody-induced (CAIA), the chronic autoim-
mune SKG, and the K/BxN serum transfer models [16–19], while anti-C5a or–C5aR blockade
is efficacious in collagen-induced (CIA) and rat antigen-induced arthritis [20, 21]. We specifi-
cally demonstrated a therapeutic effect of an anti-C5aR mAb in the CIA model, where C5aR
blockade inhibited infiltration of monocytes and neutrophils into the paw, and decreased lev-
els of several pro-inflammatory cytokines [22].
In RA monocytes migrate into the synovial tissue and differentiate into macrophages [23].
Number of synovial macrophages is correlated to level of local disease activity and joint
destruction [24, 25], and synovial macrophages have been identified as the best clinical
response marker for glucocorticosteroids, methotrexate, leflunomide and infliximab [26, 27].
Furthermore, the beneficial effect of antibodies targeting TNFα, IL-1, and IL-6 may support
the role of macrophages in RA pathogenesis, since macrophages produce high amounts of
these cytokines. Other cells, including neutrophils, also express these cytokines [28]. Neutro-
phils are the most abundant cell type in RA SF [29], and when activated produce effector mole-
cules and process endocytosed material [30–35]. Neutrophils are also found in the synovium,
mostly in the pannus/articular junction, where they are associated with complement deposi-
tion and proteoglycan degradation [36–40]. Cases where increase in neutrophil counts upon
G-CSF treatment of neutropenia in Felty’s syndrome is, furthermore, associated with RA flare
[41–43]. Finally, in RA glucocorticoids, leflunomide, methotrexate and anti-TNFα mAbs
inhibit neutrophil influx into inflamed joints [44–48]. Several lines of evidence therefore sup-
port a pathogenic role of neutrophils in RA.
C5a and C5aR in joints of rheumatoid and psoriatic arthritis patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0189017 December 8, 2017 2 / 19
collection and analysis, decision to publish, or
preparation of the manuscript. The specific roles of
these authors are articulated in the ’author
contributions’ section.
Competing interests: The study was supported by
an unrestricted grant to the Parker Institute from
the OAK Foundation, which is a philanthropic
organization. The support from Novo Nordisk A/S
did not alter our adherence to PLOS ONE policies
on sharing data and materials. The authors who
had their salaries paid by the firm [LH, AJH, DT,
MSF] were minor stockholders at the firm. This did
not give the firm any influence on the design of the
study, data collection and analysis, conclusions,
decision to publish, or preparation of the
manuscript. There are no other competing interests
to report.
Based on the hypothesis that the C5a-C5aR axis is playing a major role in initiating and/or
maintaining inflammatory joint diseases, our aim was to investigate C5a and C5aR presence in
blood and SF from RA and PsA. Our approach was first to perform immunohistochemical
analyses of synovia from one patient cohort to identify infiltrating C5aR-positive cells. Then
we measured the levels of C5a in blood and SF in another cohort to see whether these correlate
to the level of systemic and local inflammation, and to the number of neutrophils recruited to
the SF. Finally, we performed functional assays analysing the impact of C5aR blockade on neu-
trophil and monocyte migration towards patient SF.
Our results indicate that the C5a-C5aR axis is important in the onset of inflammation and
driving the influx of immune cells into the synovium in RA and PsA.
Materials and methods
The protocol for this study can be accessed from protocols.io, DOI: 10.17504/protocols.io.
kmxcu7n.
Immunohistochemistry
Human material. Human tissue samples from RA, PsA and OA, as well as from non-
inflammatory controls, used in the present study are listed in Table 1.
Ethics. All human materials were obtained with written informed consent from the
donors and approval from local ethical committees (H-4-2009 DK; BioCat Ge; Cambridge Bio-
Sciences, Supplier information: Tissue Supply Network (http://www.bioscience.co.uk)).
Sectioning. Fixed paraffin embedded cell and tissue sections were cut at a nominal thick-
ness of 3 μm, mounted on Superfrost1Plus microscope slides, and stored at -20˚C until further
processing.
Table 1. Human tissues used in the present study.
Non-inflammatory control1 Number of
samples
Provider
Synovium2,3 7 Biochain Institute Inc./BioCat GmbH, Heidelberg,
Germany
Cambridge BioScience (Cambridge, UK)
Inflamed Synovial Tissue
Rheumatoid arthritis–Synovial biopsies obtained from patients undergoing joint
replacements2,3,4
35 Biochain Institute Inc./BioCat GmbH, Heidelberg,
Germany
Cambridge BioScience (Cambridge, UK)
Rheumatoid arthritis–Synovial biopsies obtained from patients undergoing
synovectomy5,6
8 Parker Institute
Copenhagen, DK
Osteoarthritis—Synovial biopsies obtained from patients undergoing joint
replacements2,3,4,7
27 Biochain Institute Inc./BioCat GmbH, Heidelberg,
Germany
Cambridge BioScience (Cambridge, UK)
Psoriatic arthritis—Synovial biopsies obtained from patients undergoing joint
replacements2,3,4,7
10 Biochain Institute Inc./BioCat GmbH, Heidelberg,
Germany
Cambridge BioScience (Cambridge, UK)
1Histopathologically classified as being within normal limits.
2Obtained post-operational.
3Tissue microarrays (TMA) containing cores of synovial biopsies. Biopsies obtained from
4Knee
5Finger
6Wrist, and
7Hip joints.
https://doi.org/10.1371/journal.pone.0189017.t001
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Antibodies. Antibodies and conjugated detection kits used for immunohistochemical
studies are listed in Table A1 in S1 Text.
Immunohistochemical methods. Immunohistochemical (IHC) staining for C5aR and
double-immunofluorescence staining for characterization of C5aR+ cells were carried out and
is described in S1 Text.
Microscopic analyses. Sections were evaluated by virtual microscopy using either a
Hamamatsu NanoZoomer (Hamamatsu Denmark, Ballerup, Denmark), or a FV10i Laser
scanning microscope (Olympus Denmark A/S; Ballerup, Denmark), and an Olympus BX51
reflected fluorescence system microscope equipped with selective AMCA, FITC and Texas-
Red filters, and a DP70 digital camera (Olympus Denmark A/S; Ballerup, Denmark).
Flow cytometry analysis of RA synovial tissue cells
Tissue and ethics. RA synovial membranes were obtained from patients undergoing joint
replacement surgery or synovectomy at a London hospital and fulfilling the American College
of Rheumatology (ACR) criteria for RA [49], and who had given written informed consent to
participation in this study. The local ethics committee approved the study (London Riverside
Research Ethics Committee, 1752). The tissues came from 1 hip joint, 3 knee joints, 2 elbow
joints, 1 wrist joint and 2 from hand joints.
Cell preparation. Single-cell suspensions of RA synovial tissue biopsies were prepared as
described in S2 Text.
Study of matching samples of synovial fluid and blood
Patients and ethics. For assessment of paired blood and SF samples, a total of 30 patients
with active RA, 10 patients with active PsA, and 19 patients with active OA were recruited
from the day clinic at the Parker Institute, Copenhagen University Hospital, Bispebjerg and
Frederiksberg. OA was included, since it was considered to present swollen knees which were
less inflammatory than RA and PsA, and non-inflammatory controls were not available due to
ethical issues. A healthy control group (HC), 30 age- and sex-matched subjects, were recruited
via the Copenhagen City Heart Study (https://www.herlevhospital.dk/afdelinger-og-klinikker/
klinisk-biokemisk-afdeling/forskning/Sider/Herlev-oesterbroundersoegelsen.aspx), or via
advertising, for blood sampling. The study was approved by the Capital Region of Denmark’s
ethical committee (No. H-4-2009-117), and was carried out according to the Helsinki Declara-
tion (http://www.wma.net/en/30publications/10policies/b3/index.html).
For patients, inclusion criteria were: Written informed consent given; A diagnosis of RA
according to the ACR1987 criteria [49], or PsA defined according to ‘Classification criteria for
Psoriatic arthritis’ (CASPAR) [47], or OA according to the ACR-criteria [50]; Active arthritis
with joint swelling and tenderness.
Exclusion criteria were: An alcohol consumption of more than an amount equivalent to 1
unit of alcohol 12 hours or less prior to sampling; Active medical treatment for other chronic
diseases than the arthritic condition; Prior to study enrolment in active treatment with any of
the following medications: Glucocorticoid unless given in stable doses equivalent to 10 mg
of prednisone orally /day the preceding month, or intra-articular, intra-muscular or intra-
venous corticosteroids within the last month, or Cyclosporine, Azathioprine, Penicillamine,
Etanercept, Infliximab, Abatacept, Efalizumab, Alefacept, Adalimumab, intravenous immuno-
gammaglobulins (IVIG), Rituximab, or Gold therapy. During the course of the disease, it was
acceptable that the patients previously had been in active treatment with any of the above listed
medications. In such cases, the treatment must have been discontinued at least 1 month prior
to enrolment into the study.
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For HC, inclusion criteria were: Written informed consent given; Not suffering from any
disease, acute or chronic; No regular intake of medicine; Not pregnant; Not appearing to have
an alcohol problem.
Procedures. Prior to inclusion and visit, the subjects were pre-screened per telephone,
and study information was sent to possible participants. At the visit, the subject came fasting
for the assessment by a rheumatologist. Demographics and clinical data were registered, joint
scores were taken, and there was a possibility to ask questions about participation before giving
written consent. If enrolled, fasting blood test was taken, and Patient-Reported General Health
(PtGH) was assessed on a 100 mm Visual Analogue Scale (VAS) with 0 being best and 100
being worst case. Finally SF was aspirated from affected joint under ultrasound guidance.
C-Reactive protein (CRP), anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor
(RF) were measured in the blood samples, and DAS28CRP was finally calculated.
The HCs received written material prior to visit, where they were seen by a laboratory tech-
nician and had a possibility to ask questions concerning participation before giving written
consent. Then demographics were registered and fasting blood tests were taken to confirm the
health status as healthy.
Treatment of samples. From the blood samples cells isolated from EDTA-sampled full-
blood were used directly for flow cytometry, and EDTA-plasma and serum was frozen at
-80˚C for further measurements.
Cells isolated in EDTA tubes from synovial fluid were also directly used for flow cytometry.
Protocol for flow cytometry of fresh blood and SF cells. Blood and SF cells were pre-
pared and measured as described in S3 Text, particularly looking for neutrophils and mono-
cytes and presence of C5aR.
Measurements of C5a and multiplex protein analysis. Plasma and SF C5a/C5a desArg
were measured by a sandwich ELISA from BD Bioscience. In brief, microtiter plates were pre-
coated with monoclonal antibody specific for human C5a/C5a desArg. A standard was sup-
plied with the kit containing lyophilized human serum containing a specific amount of C5a
desArg. A calibrator curve was prepared by spiking C5a desArg standard into standard diluent
(animal serum), ranging from 0.078 ng/ml to 5 ng/ml. In addition, three quality control sam-
ples (QCs) were prepared covering Low (0.25 ng/ml), Medium (2 ng/ml) and High (4 ng/ml)
level of the standard curve. Any C5a/C5a desArg in the samples was bound to the plate, and
was detected by a mixture of biotinylated anti-human C5a antibody and streptavidin-HRP fol-
lowed by colorimetric detection using Tetramethylbenzidine. The plate was read at 450 nm
and reference at 620 nm on a Tecan Sunrise reader controlled by MagellanTM, Tecan Trading
AG, Switzerland. The instrument response was exported to WatsonLIMSTM software, Ther-
moFishes Scientific, where plasma concentrations were quantified.
SFs from RA patients were sent to Myriad RBM for analysis on their Human Discovery-
MAP1 175+ v1.0, a 45-biomarker Multi-Analyte Profile (MAP) designed to discern inflam-
matory biomarker patterns.
Migration assay in Boyden Chamber. Isolation of cells and the Boyden Chamber method
to look at migration of granulocytes and monocytes are described in detail in S4 Text.
For all migration studies, only assays where migration towards SFs were significantly above
migration towards medium, as determined by Student’s t-test, were included in the analysis.
Statistics
Student’s t-test was used for group comparisons, Spearman’s Rank correlation test for correla-
tions tests. Bonferoni correction was used to correct for multiple comparisons.
C5a and C5aR in joints of rheumatoid and psoriatic arthritis patients
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Results
Immunohistochemistry of synovium
IHC analyses were performed on synovial tissue samples from joint replacement from patients
with RA, PsA and OA, as well as on synovectomy biopsies from patients with RA. In synovial
samples from joint replacement, infiltrating C5aR-positive (C5aR+) cells were demonstrated in
80% of patients with RA, in 100% of patients with PsA and in 73% of patients with OA,
whereas no C5aR+ cells were infiltrating the synovium from non-inflammatory controls.
C5aR+ cells were present in the synovial lining in all groups investigated. In synovial biopsies
obtained by synovectomy, C5aR+ cells were present in 100% of patients with RA (Table 2, Fig
1). The C5aR+ infiltrating cells in OA synovial tissue were observed only when lymphoid
aggregates were present, and with fewer positive cells present compared to RA. Double-immu-
nostaining for CD68 and C5aR revealed that the majority of infiltrating C5aR+ cells in all
patient groups was CD68+ macrophages (Table 2, Fig 2A–2C). The numbers referred to in
Table 2 are given as positive samples out of the total number of samples, meaning a positive
sample harbour C5aR+ cells and a negative sample do not. PMN/macrophage C5aR negative
cells are present in the synovia, which could be explained by either a downregulation of C5aR
in macrophages or lack of activation of macrophages leading to induction of C5aR expression.
For RA patients, the frequency of C5aR+ macrophages was slightly higher in biopsy samples
compared to the findings in synovial samples from joint replacements. The C5aR+CD68+ mac-
rophages were found in the synovial sublining layer interspersed in lymphoid aggregates and
in the synovial stroma with up to 50% of the C5aR+ cells being CD68+ double-positive. All
C5aR+ cells present in the synovial lining were found to be CD68+ macrophage-like synovio-
cytes. Germinal centres were not seen in the lymphoid aggregates. Double immunostainings
for C5aR and CD3 (T cell marker), showed that in none of the diseased synovial samples (RA;
OA and PsA) did CD3+ T cells express C5aR, but the C5aR+ cells were found in close proxim-
ity to the T cells (Table 2, Fig 2D). This observation might indicate the physical possibility of
an indirect activation of T cells from C5aR+ cells.
Immunostaining for Myeloid peroxidase (MPO neutrophil marker) showed profound infil-
tration of neutrophils into the synovium from patients undergoing joint replacements in 58%
of RA, in 88% of PsA, and 26% of OA patients, while no neutrophils were found in the syno-
vium of non-inflammatory controls (Table 2). While 90% of neutrophils located in the lumen
of synovial blood vessels were C5aR-positive, as determined by double staining for MPO and
C5aR, only 5% of the neutrophils infiltrating the synovium from either RA or OA patients
undergoing joint replacement were C5aR+ (Fig 2E). In contrast, up to 25% of the extravascular
Table 2. Summary of C5aR expression and characterization of C5aR-positive cells in the synovium from patients with RA, OA, PsA and from non-
inflammatory controls.
Cell type RA1
Joint replacement
RA1
Synovectomy
OA1 PsA1 Non-inflammatory control1,2
C5aR+ cells 28/35 8/8 11/15 10/10 3/7*
C5aR+MPO+ neutrophils 11/19 6/8 7/27 7/8 0/7
C5aR+CD68+ macrophages 11/16 7/7 10/21 7/7 3/4*
C5aR+CD3+ T cells 0/19 ND 0/27 0/2 0/5
1Number of positive samples/total number of samples included in the study.
2Histopathologically classified as being within normal limits.
Abbreviations: ND: Not done; OA: Osteoarthritis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis.
*Single or double-positive cells present in synovial lining.
https://doi.org/10.1371/journal.pone.0189017.t002
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neutrophils in PsA and in RA samples obtained by synovial biopsies were double-positive for
C5aR and MPO (Fig 2F). In all patient groups were the vast majority of intravascular MPO+
neutrophils found to be C5aR+.
Fig 1. C5aR expression in the synovium from rheumatoid arthritis, osteoarthritis psoriatic arthritis, and non-inflammatory
control. Immunohistochemical staining for C5aR (A, B, C, E and F), and for the IgG2a isotype control antibody (D). Synovium from
patients with RA undergoing joint replacement is shown in (A), and synovectomy, (C, D). Synovium from patients with OA is shown
in (E), and PsA in (F). Synovium from a non-inflammatory control is seen in (B). Numerous infiltrating C5aR+ cells (in brown) are
seen in A, C and F. Intravascular C5aR+ neutrophils are seen in C and E (arrowheads). Note the lack of immunoreactivity in the non-
inflammatory control (B). Nuclei (in blue) were counterstained with haematoxylin. Bars: (A, B, E and F) 50 μm, (C and D) 100 μm.
https://doi.org/10.1371/journal.pone.0189017.g001
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Fig 2. C5aR expression by macrophages and neutrophils, but not by T cells in the synovium of rheumatoid arthritis.
Double immunofluorescence staining for C5aR (red signal A—F) and either CD68+ macrophages (green signal A, B and C), CD3+
T cells (green signal in D), or MPO+ neutrophils (green signal in E and F) of the synovium from rheumatoid arthritis patients
undergoing joint replacement (A, B, D and E) or synovectomy (C and F), analysed by confocal microscopy (A, B, D and E) and
epifluorescence microscopy (C and F). Framed area in E is seen in B. Note the co-localization of C5aR and CD68+ macrophages in
A, B and C, and MPO+ neutrophils F, and lack of co-localization with a CD3+ T cell in D. The nuclei (in blue) were counterstained
with Hoechst. Bars: (A) 100 μm, (B and D) 5 μm, (E) 500 μm, (C and F) 50 μm.
https://doi.org/10.1371/journal.pone.0189017.g002
C5a and C5aR in joints of rheumatoid and psoriatic arthritis patients
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Flowcytometry of RA synovial cells
To assess the frequency of cell subsets of macrophages and infiltrating neutrophils present in
RA synovial tissue, flowcytometry measurements of present neutrophils and macrophages
were carried out on explants obtained from synovium from joints from nine RA patients were
obtained. A detailed flowcytometry analysis of freshly isolated cells surface expression of C5aR
confirmed the immunohistochemical findings described above. Infiltrating neutrophils and
macrophages constituted 1.3% and 50%, respectively, of infiltrating CD45+ cells in the assessed
synovia. The percentage of cell subsets varied between individuals. Within the viable hemato-
poietic cell compartment, CD14+ macrophages were most abundant, ranging from 23 to 70%
of CD45+ cells, followed by T cells (6 to 30% of CD45+ cells).
Flowcytometry of SF cells
Demographic data on participating patients is given in Table 3. In synovial fluids from RA and
PsA patients, all neutrophils and monocytes expressed C5aR. Neutrophil and monocytes con-
stituted on average 37% and 9% of the cells in the SF cells in RA, 58% and 7% in PsA patients.
For comparison, these were 5% and 9% in OA, thereby questioning OA as a non-inflammatory
control for the others.
C5a levels in SF
The level of C5a in SF from RA and PsA patients was compared to the level found in OA
patients. These were considered the best non-inflammatory controls available, although low
inflammation is likely to be present due to the presence of a swollen knee and the above
described findings of neutrophils and monocytes in SF. C5a levels in RA patients were found
to be significantly elevated in RA compared to OA. The same was the case for PsA (Fig 3A).
In plasma the C5a level in RA was elevated relative to healthy controls (demographic data
see Table 3), but not relative to OA (Fig 3B).
In RA, SF C5a correlated both to DAS28 and to the plasma CRP level (p< 0.01 and
p< 0.0001, respectively. For PsA, SF C5a correlated to DAS28 (p< 0.01) but not to plasma
Table 3. Demographic data on the subjects providing blood and synovial fluid.
Male/
Female
Median Age (Range) Years
Male/
Female
Disease
Duration
Months
Male/
Female
±RF
Male/
Female kIU/l
±anti-CCP
Male/
Female
U/l
CRP
Male/
Female mg/l
DAS28CRP
Male/
Female
RA 4/25 62(52–76)/
60(33–79)
85,5/
121,1
+RF: 4/10
RF: 0/15
+anti-CCP: 3/11
anti-CCP: 1/14
7,25/
15,6
3,91/
3,78
PsA 4/7 36(36–40)/
63(29–66)
177/
69,4
+RF: 0/0
RF: 4/7
+anti-CCP: 0/0
anti-CCP: 4/7
69/
12,3
4,40/
3,42
OA 8/10 64(45–74)/
72(56–85)
35,6/
108,7
+RF: 1/0
RF: 7/10
+anti-CCP: 0/0
anti-CCP: 8/10
2,75/
2,5
2,91/
3,07
HC 8/24 52(32–72)/
55(35–79
- *+RF: 1/1
*RF: 7/22
+anti-CCP: 0/0
anti-CCP: 8/24
1,13/
1,30
-
+RF is defined as RF> 7 kIU/l
*One HC was not measured for RF. The two +RF were boarder-line +RF with 8 and 9 kIU/l. +anti-CCP is defined as <7 U/l. Disease duration is taken from
date for diagnosis.
https://doi.org/10.1371/journal.pone.0189017.t003
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CRP, although a tendency was observed (Spearman’s Rank correlation coefficient = 0.4338),
Fig 4.
Disease duration and levels of rheumatoid factor (RF) and/or anti-citrullinated protein
antibodies (ACPAs) were not correlated to C5a levels. C5a plasma levels were in RA found to
be correlated to the levels found in SF (Spearman’s Rank correlation coefficient = 0.4338;
p = 0.0003), but not in PsA, although a tendency was observed (Spearman’s Rank correlation
coefficient = 0.4273).
Inflammatory markers in RA
RA SF samples were further subjected to a multiplex protein analysis and C5a levels were cor-
related to the measured inflammatory markers.
To correct for multiple comparisons, only markers where correlation to C5a is significant
after Bonferoni correction of p-values were considered. A number of acute phase reactants
(von Willebrand factor, Alpha-1-antitrypsin, CRP, Alpha-2-macroglobulin, haptoglobin and
complement factor 3), a number of cytokines (IL-6, IL-10, IL-1RA, IL-1β, IFNγ) in addition to
MMP9, soluble ICAM-1, soluble TNFR2, Factor VII and TIMP-1 were positively correlated to
C5a, while MMP3 was negative correlated to C5a, Table 4.
Fig 3. C5a levels in synovial fluids and plasma. A. Synovial fluid levels. B. Plasma levels. Statistical
analysis was with the Student’s t-test. P-values are uncorrected for multiple testing.
https://doi.org/10.1371/journal.pone.0189017.g003
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Statistics were carried out using the Spearman’s Rank correlation coefficient. Uncorrected
p-values are given, but all the p-values are significant also after Bonferoni correction. Markers
not fulfilling this criterion, but still positively correlated to C5a if no correction is performed,
were CCL3, IL-8 and TNFα (all with p-values < 0.01), CCL4, VEGF, IL-4, IL12p40, IL-17A,
IL-7, fibrinogen and soluble VCAM (all with p-values < 0.05). Stem cell factor was negatively
correlated to C5a (p< 0.01).
Immune cell migration
To test the importance of C5a in chemo-attraction of granulocytes and monocytes to SFs from
RA and PsA patients, the effect of a blocking anti-human C5aR mAb on leukocyte migration
was determined using a Boyden chamber system. For RA SFs, granulocyte migration was sig-
nificantly inhibited (p = 0.014) with an average inhibition of 60%, ranging from no inhibition
to total inhibition, while monocyte migration was also significantly inhibited (p = 0.0012) with
an average inhibition of 33%, ranging from no inhibition to total inhibition (Fig 5A). For a sin-
gle subject, anti-C5aR treatment increased migration (corrected p-value < 0.05). We have no
explanation for this. As it seemed that C5aR may have the largest effect on granulocyte migra-
tion into the joint, we also investigated if C5a levels in RA SF correlated to the percentage of
neutrophils in SF. A significant correlation between levels of C5a and the relative proportion
of neutrophils in SF from RA patients was indeed found (p< 0.0001; Spearman r = 0.082) (Fig
5B). Similar data were obtained when using the absolute number of neutrophils in the synovial
fluids (p< 0.0001; Spearman r = 0.081). We only obtained data from 7 PsA SFs for granulocyte
migration and from 2 PsA SFs for monocyte migration: Granulocyte migration was inhibited
with an average inhibition of 79% (ranging from no inhibition to total inhibition), but this was
not significant (p = 0.08). Monocyte migration inhibited 42% in one sample, but not at all in
the other sample. There was no indication of a correlation of C5a levels to neutrophil propor-
tion in the PsA SFs.
Fig 4. C5a levels in synovial fluids correlate to disease activity. A and B: From RA patients; synovial fluid
C5a levels correlate to both DAS28 and plasma CRP (r values of respectively 0.5122 (p = 0.0075) and 0.6881
(p < 0.0001). C and D: From PsA patients; synovial fluid C5a levels correlate to DAS28 and plasma CRP (r
value = 0.7727 (p = 0.0053), but not to CRP. Statistical analysis was with Spearman’s Rank correlation test.
https://doi.org/10.1371/journal.pone.0189017.g004
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C5a –C5aR correlation
Since C5a ligation leads to C5aR internalization, we investigated whether there was inverse
correlation between C5a and C5aR on SF neutrophils and monocytes, as this would indicate
that these cells had been subject to ligand binding. This was indeed the case: C5a exhibited
inverse correlation to C5aR expression on both neutrophils (p = 0.0036 and Spearman’s Rank
correlation coefficient = -0.5928) and monocytes (p = 0.0010 and Spearman’s Rank correlation
coefficient = -0.6291) in SF from RA patients.
Discussion
Our immunohistochemical investigations showed that C5aR-positive cells are infiltrating the
synovial tissues of RA, PsA and OA patients, while no extravascular C5aR-positive cells are
found in samples from non-inflammatory controls. Looking at RA, C5aR+ cells were found in
80% of the samples taken during joint replacement, and in 100% of samples obtained from
synovectomy. The latter represents more active disease which is supported by the higher inci-
dence of C5aR-positive cell. The two findings indicate an involvement of C5a/C5aR in the
inflammatory process.
Presence of C5aR in inflamed synovial tissue from RA patients is reported before [51], but
not further defined. We demonstrated that the majority of C5aR-positive cells in RA syno-
vium, as well as in PsA and OA, were macrophages as determined by double-immunostaining
for C5aR and CD68. We also observed that the C5aR+ cells were found in close proximity to
the T cells. Although we have no data indicating any functional relevance of this observation,
it is likely that the interaction plays a pathogenic role–either in contributing to local T-cell acti-
vation by antigen presentation by the myeloid cells to the T cell and/or to macrophage activa-
tion by the T cells. In this connection it must be noted that a direct role of the C5a-C5aR axis
in T-cell activation by antigen-presenting cells have been observed, although this is disputed
[11, 52, 53]. However, also C5aR-positive neutrophils were detected, albeit most infiltrating
neutrophils were C5aR-negative. This may indicate that these neutrophils down-regulated
Table 4. Biomarkers in RA SF correlating to C5a levels.
Marker r-value p-value
Von Willebrand factor 0.8403 < 0.0001
MMP9 0.8332 < 0.0001
IL-6 0.8134 < 0.0001
IL-10 0.8133 < 0.0001
IL-1RA 0.7354 < 0.0001
IL-1β 0.7302 < 0.0001
Alpha-1-Antitrypsin 0.7298 < 0.0001
ICAM-1 0.7297 < 0.0001
CRP 0.6951 < 0.0001
Alpha-2-Macroglobulin 0.6785 0.0001
Haptoglobin 0.6655 0.0002
Complement C3 0.6541 0.0002
TNFR2 0.6579 0.0003
IFNγ 0.6379 0.0003
Factor VII 0.6248 0.0005
TIMP-1 0.6235 0.0005
MMP3 -0.7994 < 0.0001
https://doi.org/10.1371/journal.pone.0189017.t004
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C5aR after extravasation, since the vast majority of intravascular neutrophils were found to be
C5aR-positive, as expected. Although the presence of neutrophils in the synovial fluid of RA
patients is well-known [54], the detection of infiltrating neutrophils in the synovium is less rec-
ognized, despite of earlier reports [37, 40, 55]. These studies also report much fewer neutro-
phils present in synovium from OA patients–in agreement with our observations.
When measuring the level of C5a in SFs from RA patients, we confirmed increased C5a
level in RA SF when compared to OA [12, 13]. We also showed C5a level to be correlated to
DAS28. This is in agreement with earlier studies demonstrating that complement activation in
SF of RA patients correlates to disease activity [5, 6], and specifically to DAS28 [7]. No correla-
tion of C5a to RF was observed. This is in agreement with Doherty et al [5], but in opposition
to Wouters et al [7]. However, in the latter study the level of RF correlates to DAS28. It could
Fig 5. Anti-C5aR mAb inhibition of migration towards RA synovial fluids. A. PML and monocyte
migration. All values were normalized by setting the migration with isotype control mAb added to 100. Average
inhibition by anti-C5aR mAb was 60% (p = 0.014) for PMLs (n 0 16) and 33% (p = 0.0012) for monocytes
(n = 22). B. Relative neutrophil number vs. C5a levels in RA SF. Percentage neutrophils in the synovial fluid
correlate to synovial fluid C5a levels (r value = 0.8182; p < 0.0001). Statistical analyses were Student’s paired
t-test in A and Spearman’s Rank correlation test in B.
https://doi.org/10.1371/journal.pone.0189017.g005
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therefore be concluded that complement activation correlates to disease activity, but not to RF
independently of this. The finding indicates that RF-containing immune complexes may not
be driving complement activation in RA patients, in opposition to what has earlier been pro-
posed [56]. We also did not see any correlation to ACPA titers. In summary, our results indi-
cate that complement activation in patients with RA may not be due to activation of the
classical pathway by immune complexes. Alternatively, it could happen via CRP, as suggested
by others [57], since C5a levels correlate to CRP levels, both in SF and in plasma. Many other
immunomodulatory markers correlated to local C5a titers. These included other acute phase
reactants and the proinflammatory (IL-6, IL-1β and IFNγ) and anti-inflammatory cytokines
(IL-1Ra and IL-10). This clearly indicates a correlation between local complement activation
and acute inflammation. We observed a surprising inverse correlation between C5a and
MMP3 in synovial fluids from RA patients. This is in opposition to other studies, where
MMP3 correlates to other proinflammatory biomarkers [58], and we have no explanation for
this apparent discrepancy.
To explore if C5a could be driving synovial influx in RA patients, we performed migration
assays of neutrophils and monocyte towards synovial fluids from RA patients. Here we dem-
onstrated that treatment with a blocking anti-C5aR mAb significantly reduced the migration
of both cell types. This implies that pharmaceutical targeting of the C5a-C5aR axis may reduce
synovial influx of both monocytes and neutrophils, as is indicated by earlier animal studies
[15, 17, 19, 22]. A further indication of the importance of the C5a/C5aR in the described cell
migration process is the finding that levels of C5a and the number of neutrophils in synovial
fluid correlate.
In summary, we have provided data to support that the C5a-C5aR axis may be involved in
the pathogenesis of RA. However, an oral C5aR antagonist, PMX53, was investigated in a
small clinical trial of patients with RA, and that no effect on clinical score, macrophage infiltra-
tion or cytokine expression in synovia [59]. It should be noted that pharmacokinetic reporting
in this study was limited to reporting of area under the curve, and that it is highly likely that
the target was not inhibited at all times by the once daily dosings. Futhermore, it has later
appeared that PMX53 is an agonist of Mas-related gene X2 (MrgX2) and via this receptor can
induce mast cell degranulation [60, 61].The anti-C5 antibody, eculizumab, has also been
reported to lack efficacy in patients with RA [1], although details has not been published.
Again, it can be speculated that doses were too low, since the approved indications of eculizu-
mab concerns C5-cleavage in the blood stream, so doses used there may not be sufficient for
blocking C5-cleavage in a tissue, where an antibody will have limited access.
For PsA we obtained results similar to those obtained from RA patients: C5a titers were
increased in synovial fluids, and titers correlated to DAS28 (albeit not to CRP levels). There
was a tendency that anti-C5aR mAb inhibited neutrophil migration to PsA SFs, but this was
not significant. When looking at OA, the SF showed invasion of immune cells, although not to
the degree as seen in RA and PsA. Thus, OA cannot be considered a non-inflammatory con-
trol, but must be considered as a low-grade inflammation in the OA patients appearing with a
swollen joint.
Conclusion
The C5a-C5aR axis is important in the onset of inflammation and driving the influx of
immune cells into the synovium in RA and PsA. The pathway may be a relevant target for
treatment of these patients.
A larger study is though warranted to substantiate this in PsA.
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OA is not a valid non-inflammatory model when comparing arthritic diseases due to a
varying inflammatory profile.
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